GlassScriptPhysician profile
Isabel Vega
NPI 1316073430
$6,289.88
in general payments reported to CMS, 2019-2025
33 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,898 · 2020: $329 · 2021: $164 · 2022: $1,611 · 2023: $1,275 · 2024: $642 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,289.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,322.77 | 2019-2025 | Rinvoq, Skyrizi |
| Astrazeneca Pharmaceuticals LP | $927.86 | 2019-2025 | Saphnelo, Airsupra |
| Glaxosmithkline, LLC. | $710.86 | 2019-2025 | Benlysta, Trelegy Ellipta |
| Janssen Biotech, INC. | $668.77 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $609.45 | 2019-2024 | Enbrel, Tavneos, Otezla |
| Genentech USA, INC. | $525.78 | 2019-2023 | Actemra |
| Pfizer INC. | $246.24 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $162.10 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.51 | 2019-2024 | Cyltezo, Ofev, Jardiance |
| Lilly USA, LLC | $141.99 | 2019-2024 | Taltz, Jardiance |
| Regeneron Healthcare Solutions, INC. | $128.84 | 2019 | |
| Ucb, INC. | $84.74 | 2019-2022 | |
| Novo Nordisk INC | $72.94 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $57.91 | 2022 | |
| Abbott Laboratories | $51.92 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.79 | 2019 | |
| Radius Health, INC. | $34.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.07 | 2019 | |
| Mallinckrodt Enterprises LLC | $33.68 | 2019 | |
| Grifols USA, LLC | $32.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.14 | 2019 | |
| Sobi, INC | $26.07 | 2022 | |
| Fresenius Kabi USA, LLC | $22.63 | 2023 | Idacio |
| Horizon Therapeutics Plc | $22.61 | 2023 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $19.90 | 2024 | Voquezna |
| Astellas Pharma US INC | $19.37 | 2020 | |
| Pylant Medical | $19.13 | 2022 | |
| Sanofi Pasteur INC. | $17.23 | 2019 | |
| Exact Sciences Corporation | $16.66 | 2024 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $15.93 | 2023 | |
| Allergan, INC. | $15.75 | 2019 | |
| Aurinia Pharma U.S., INC. | $15.12 | 2022 | |
| Merck Sharp & Dohme LLC | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Vega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.